Understanding the power and appropriate application of QSP is critical!

In this webinar, Lisl Shoda and Steve Chang will explain the value of QSP in drug development, as well as common and innovative applications. They’ll share case studies of how the use of QSP has influenced decision-making and program direction in a variety of therapeutic areas, including in the liver disease, lung disease, oncology, and autoimmune disease spaces.

Register Here

Novice & Advanced Users
Workshops

Online Learning

• Advanced GastroPlus® DMPK and Clinical Pharmacology Workshop: Tokyo, Japan
  • Nov. 16th-17th
• Advanced GastroPlus Phamaceutical Development Workshop: Tokyo, Japan
  • Nov. 16th-17th
• Complimentary Introduction to GastroPlus Workshop
  • Oct. 31st
  • Dec. 4th
• Complimentary Introduction to GastroPlus Workshop (EU)
  • Oct. 3rd
• GastroPlus Advanced Workshop: DMPK and Clinical Pharmacology
  • Sept. 18th-21st
• GastroPlus Application Based DDI Workshops
  • Oct 9th-Nov 10th
• GastroPlus Advanced Workshop: Pharmaceutical Development
  • Nov. 28th-Dec.1st
• Introduction to GastroPlus Workshop
  • Oct. 9th-13th
• Introductory Workshop in Population PK Data Analysis
  • Sept. 25th – Oct 6th
• Introductory GastroPlus Workshop: Tokyo, Japan
  • Nov. 13th-15th
• PharmoGo: GastroPlus Modeling and Simulation Workshop
  • Sept. 14th-23rd
• Pharmacometrics Modeling & Simulations Using MonolixSuite™: From Introductory to Advanced Concepts and Applications
  • Nov. 9th-10th

On-Demand Courses (Now Available)

• Transdermal Administration (TCAT™) in GastroPlus®
• Injectables (IM, SQ, IA) in GastroPlus Including Biologics and LAIs
• Ocular Administration (OCAT™) in GastroPlus®
• Pulmonary Administration (PCAT™) in GastroPlus®
• GastroPlus® ADR – 4 Course Bundle (TCAT™ / OCAT™ / OCCAT™ / PCAT™)
• GastroPlus® ADR – 5 Course Bundle (TCAT™ / OCAT™ / OCCAT™ / PCAT™ / Injectables)

View Upcoming Workshops

Meet Us In Person
Conferences

2023 ACCP Annual Meeting Sept. 10th-12th, Bellevue, WA

• Booth #7
• Attendees: Joshua Stangl, Christina Hendrickson, Jill Fiedler-Kelly, Tom Sun, Stefan Roepcke, Mitali Gaurav, Steve Chang

EuroTox 2023 – Sept.10th-13th, Ljubljana, Slovenia

• Presentation: Predictive performance of physiologically based kinetic (PBK) models based on in-silico/in vitro- in vivo extrapolation (IS/IVIVE)
• Presenter: Priyata Kalra

65th Congress of the Polish Chemical Society Sept. 18th-22nd, Torun, Poland

• Presentation: Application of AIDD for RORgamma nuclear receptors
• Presenter: Rafal Bachorz

GMP 2023 Symposium (Groupe de Métabolisme et Pharmacocinétique) 
Oct. 18th-20th, Paris, France

• Pre-Conference Workshop: First in Human (FIH) Dose Selection: from Basic Concepts to Novel Considerations        Oct. 17th
• Workshop: Pediatric PBPK workshop using GastroPlus® Oct. 18th

AAPS 2023 PharmSci 360 Oct. 22nd-25th, Orlando, FL

• Booth #2301
• Presentations:
  • Presentation: Development of a Quantitative Systems Toxicology Model to Predict Drug-Induced Liver Injury in Pediatrics.
  • Presenter: An Do Dela
  • Presentation: Physiologically Based Pharmacokinetic (PBPK) Oral Absorption Model to Predict Mucosal Permeability of Oral Cavity Drug Products.
  • Presenter: Priyata Kalra

View Events Calendar

Take Advantage 
Latest Offers

• Unleash the power of AI for early drug discovery
• Streamline PBPK and QSP workflows with our Pulmonary Package
• Train your team during our next consulting project with Consult + Coach

Contact us for Details

• Simulations Plus Chief Science Officer Dr. Viera Lukacova Honored as Fellow by the American Association of Pharmaceutical Scientists (AAPS)

• Halloysite nanotubes-cellulose ether based biocomposite matrix, a potential sustained release system for BCS class I drug verapamil hydrochloride: Compression characterization, in-vitro release kinetics, and in-vivo mechanistic physiologically based pharmacokinetic modeling studies
• PB2205: A Mechanistic Absorption and Pharmacokinetic Model of Covalent BTK Inhibitor TL-895: Influence of Food and Acid Reducing Agents
• Quantitative Systems Toxicology identifies independent mechanisms for hepatotoxicity and bilirubin elevations due to AKR1C3 Inhibitor BAY1128688
• Assessing Liver Effects of Cannabidiol and Valproate Alone and in Combination Using Quantitative Systems Toxicology

Read up on New Research

Can’t Miss

Upcoming Webinars

• In Vitro and In Silico Predictions of Orally Inhaled Drug Product In Vivo Performance
• QSP: The Best Kept Secret for Increasing the Technical Probability of Success in Clinical Trials & Enhancing Regulatory Submissions
• The GastroPlus PBPK Modeling Webinar Series
• Application of PBBM and virtual bioequivalence to support formulation development and define dissolution specification, two case studies

View All Webinars